- Home
- CPRI vs GLPG Comparison
CPRI vs GLPG Comparison
Compare CPRI & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRI
- GLPG
- Stock Information
- Founded
- CPRI 1981
- GLPG 1999
- Country
- CPRI United Kingdom
- GLPG Belgium
- Employees
- CPRI N/A
- GLPG N/A
- Industry
- CPRI Apparel
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- CPRI Consumer Discretionary
- GLPG Health Care
- Exchange
- CPRI Nasdaq
- GLPG Nasdaq
- Market Cap
- CPRI 2.2B
- GLPG 2.1B
- IPO Year
- CPRI 2011
- GLPG 2005
- Fundamental
- Price
- CPRI $21.33
- GLPG $32.00
- Analyst Decision
- CPRI Buy
- GLPG Sell
- Analyst Count
- CPRI 11
- GLPG 4
- Target Price
- CPRI $23.64
- GLPG $25.33
- AVG Volume (30 Days)
- CPRI 3.6M
- GLPG 407.4K
- Earning Date
- CPRI 08-06-2025
- GLPG 07-23-2025
- Dividend Yield
- CPRI N/A
- GLPG N/A
- EPS Growth
- CPRI N/A
- GLPG N/A
- EPS
- CPRI N/A
- GLPG N/A
- Revenue
- CPRI $4,391,000,000.00
- GLPG $323,674,692.00
- Revenue This Year
- CPRI N/A
- GLPG N/A
- Revenue Next Year
- CPRI $4.35
- GLPG N/A
- P/E Ratio
- CPRI N/A
- GLPG N/A
- Revenue Growth
- CPRI N/A
- GLPG 5.43
- 52 Week Low
- CPRI $11.86
- GLPG $22.36
- 52 Week High
- CPRI $43.34
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- CPRI 58.11
- GLPG 53.21
- Support Level
- CPRI $19.25
- GLPG $31.32
- Resistance Level
- CPRI $22.18
- GLPG $32.63
- Average True Range (ATR)
- CPRI 1.06
- GLPG 0.71
- MACD
- CPRI 0.18
- GLPG -0.25
- Stochastic Oscillator
- CPRI 75.28
- GLPG 29.13
About CPRI Capri Holdings Limited
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. Capri also owns a third brand, Versace, but has agreed to sell it to Prada. John Idol has served as Capri's CEO since 2003.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.